El interés en corto de Fulgent Genetics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Fulgent Genetics. Los datos de interés en corto se actualizan cada dos semanas.

Fulgent Genetics (NASDAQ:FLGT) Bolsa, Informe de interés en corto

Fulgent Genetics

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics Inc

Why allow intermediaries to add unnecessary costs when direct relationships can bring quality to the forefront? As supply chains tighten across industries, Red Mesa Science &amp; Refining is pioneering a streamlined approach to bring minor cannabinoids to market.&nbsp;
By bypassing brokers and relying on an efficient, around-the-clock refinement process, Red Mesa aims to reduce costs, ensure product consistency and empower the true stewards of hemp &#8211; the growers and refiners themselves. 
Jeff Applegate, Red Mesa's president, puts it simply. "Collaborating directly with qualified, experienced farmers and extractors is essential to keeping costs low and quality high." It's a model that prioritizes trust and accountability within every step of the supply chain.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h2 class="wp-block-heading">Leverage Instead Of Liability</h2>
Applegate detailed how brokers often disrupt the hemp supply chain by imposing additional costs, sometimes up to 15%, which can hinder farmer&#8217;s profits and drive up expenses for manufacturers, creating an unsustainable model for both sides.
Red Mesa has strategically positioned itself within the cannabinoid supply chain to minimize intermediaries and maintain competitive production costs. "Keeping production costs low is fundamental to industry success," Applegate told Benzinga Cannabis in an exclusive interview. "Collaborating directly with farmers and extractors in a cohesive supply chain is essential to keep our cost of input as a leverage instead of a liability."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165714/In-proces-testing-Bulk-CBD-Isolate-Red-Mesa-Science-and-Refining-copy-1024x590.jpg" alt="" class="wp-image-636416" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165714/In-proces-testing-Bulk-CBD-Isolate-Red-Mesa-Science-and-Refining-copy-1024x590.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165714/In-proces-testing-Bulk-CBD-Isolate-Red-Mesa-Science-and-Refining-copy-300x173.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165714/In-proces-testing-Bulk-CBD-Isolate-Red-Mesa-Science-and-Refining-copy-768x442.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165714/In-proces-testing-Bulk-CBD-Isolate-Red-Mesa-Science-and-Refining-copy-1536x884.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165714/In-proces-testing-Bulk-CBD-Isolate-Red-Mesa-Science-and-Refining-copy.jpg 1876w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">In-proces testing Bulk CBD Isolate Red Mesa Science and Refining. </figcaption></figure>
"We're seeing less interference now, but reducing reliance on brokers is essential for a cost-effective system. The farmer and the customer need to be directly tied to one another so the farmer gets a fair return," he explained.&nbsp;
<h3 class="wp-block-heading">Not An Easy Crop</h3>
Sourcing consistent and affordable raw materials has presented a challenge as the hemp industry matures. Applegate explained that an initial oversupply in 2019 led to a rapid decline in hemp farming as prices plummeted. 
"There was an abundance of farmers when the 2018 farm bill was put into place," he said. "The market, the producers, wasn't sufficiently equipped to take all of the output that came. Since 2019, we've had nothing but a declining number of farmers."
"It's not an easy crop to grow at all," Applegate added, noting that hemp requires extensive processing before it can be used in extraction. This contrasts with the cannabis flower market, where crops can be more directly sold.
Read Also: <a href="https://www.benzinga.com/news/24/09/40941818/how-this-cheese-aging-tech-is-boosting-profits-for-cannabis-growers-stop-throwing-cheddar-out-the-do">How This Cheese-Aging Tech Is Boosting Profits For Cannabis Growers: Stop Throwing Cheddar Out The Door</a>
<h2 class="wp-block-heading">Inside Red Mesa&nbsp;</h2>
Red Mesa's facility in Utah was initially a cabinet shop before being repurposed for hemp refinement. With its high power capacity &#8211; essential for their machinery &#8211; the location proved ideal. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="665" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165821/Liquid-Chromatography-Red-Mesa-Science-and-Refining-for-CBD-CBG-CBN-CRD-Isolates-and-Distillates-1024x665.jpg" alt="" class="wp-image-636418" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165821/Liquid-Chromatography-Red-Mesa-Science-and-Refining-for-CBD-CBG-CBN-CRD-Isolates-and-Distillates-1024x665.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165821/Liquid-Chromatography-Red-Mesa-Science-and-Refining-for-CBD-CBG-CBN-CRD-Isolates-and-Distillates-300x195.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165821/Liquid-Chromatography-Red-Mesa-Science-and-Refining-for-CBD-CBG-CBN-CRD-Isolates-and-Distillates-768x499.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165821/Liquid-Chromatography-Red-Mesa-Science-and-Refining-for-CBD-CBG-CBN-CRD-Isolates-and-Distillates-1536x998.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165821/Liquid-Chromatography-Red-Mesa-Science-and-Refining-for-CBD-CBG-CBN-CRD-Isolates-and-Distillates.jpg 1663w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Liquid Chromatography Red Mesa Science and Refining for CBD CBG CBN CRD Isolates and Distillates. </figcaption></figure>
Applegate described how the production process flows from crude oil intake to distillation. This is further refined through crystallization and chromatography. "In distillation, we have the finished product. It's usually a light yellow to golden color, thicker in viscosity than water, almost syrup-like when warm," he explained.
Once the distillate undergoes crystallization, Red Mesa is left with a white, fluffy powder—ready for B2B sale. "We didn't walk across the bridge to become a white labeler or finished goods company," he said. "Our goal is to create the most coveted, consistent outputs to win the market."
<h3 class="wp-block-heading">A Competitive Edge In Minor Cannabinoids</h3>
Red Mesa's botanical, non-synthetic refinement process sets it apart by isolating rare cannabinoids—such as CBN, CBT, and CBL—directly from hemp without chemical conversions.&nbsp;
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165933/Gate-1-Red-Mesa-Science-and-Refining--1024x557.jpg" alt="" class="wp-image-636421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165933/Gate-1-Red-Mesa-Science-and-Refining--1024x557.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165933/Gate-1-Red-Mesa-Science-and-Refining--300x163.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165933/Gate-1-Red-Mesa-Science-and-Refining--768x418.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165933/Gate-1-Red-Mesa-Science-and-Refining--1536x836.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07165933/Gate-1-Red-Mesa-Science-and-Refining-.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Gate 1 Red Mesa Science and Refining</figcaption></figure>
"Our botanical refining process generates final outputs derived directly from the hemp plant without the use of catalysts and acids required for chemical conversion processes," Applegate explained.
To achieve this, Red Mesa made substantial investments early on. "To be the first refiner to offer rare minors such as CBN, CBL, and CBT at kilogram scale, we had to make significant investments in large-scale chromatography very early in the company's history," Applegate noted. 
Read Also:<a href="https://www.benzinga.com/general/biotech/24/10/41394513/sold-out-before-hitting-shelves-why-did-ayr-wellness-snatch-up-this-local-cannabis-brand"> Sold Out Before Hitting Shelves: Why Did AYR Wellness Snatch Up This Local Cannabis Brand?</a>
<h3 class="wp-block-heading">The Red Mesa Standard: ISO Certification, And FDA Registration</h3>
&#8220;The Red Mesa Standard&#8221; represents a commitment to quality and consistency that Applegate says will set them apart. "We have an end-to-end certification from the beginning of our business to the end," he said, contrasting this with many industry peers who only certify specific departments. Additionally, Red Mesa voluntarily registers with the FDA as a food ingredient company, even though it's not required.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="422" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170058/Dual-Liquid-Chromatography-System-Refines-and-Purifies-CBN-Isolate-Botanical-CBN-Disitllate-Botanical-CBL-CBT-Red-Mesa-Science-and-Refining-copy-1024x422.jpg" alt="" class="wp-image-636425" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170058/Dual-Liquid-Chromatography-System-Refines-and-Purifies-CBN-Isolate-Botanical-CBN-Disitllate-Botanical-CBL-CBT-Red-Mesa-Science-and-Refining-copy-1024x422.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170058/Dual-Liquid-Chromatography-System-Refines-and-Purifies-CBN-Isolate-Botanical-CBN-Disitllate-Botanical-CBL-CBT-Red-Mesa-Science-and-Refining-copy-300x124.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170058/Dual-Liquid-Chromatography-System-Refines-and-Purifies-CBN-Isolate-Botanical-CBN-Disitllate-Botanical-CBL-CBT-Red-Mesa-Science-and-Refining-copy-768x316.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170058/Dual-Liquid-Chromatography-System-Refines-and-Purifies-CBN-Isolate-Botanical-CBN-Disitllate-Botanical-CBL-CBT-Red-Mesa-Science-and-Refining-copy-1536x633.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170058/Dual-Liquid-Chromatography-System-Refines-and-Purifies-CBN-Isolate-Botanical-CBN-Disitllate-Botanical-CBL-CBT-Red-Mesa-Science-and-Refining-copy.jpg 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Dual Liquid Chromatography System Refines and Purifies CBN Isolate &#8211; Botanical CBN Disitllate &#8211; Botanical CBL CBT Red Mesa Science and Refining.</figcaption></figure>
<h3 class="wp-block-heading">24/7</h3>
With operations currently running at about 45% of their <a href="https://www.youtube.com/watch?v=_lpxdoVtWow">50,000-square-foot facility</a>, Red Mesa is poised for growth. "We operate 24 hours a day, seven days a week," Applegate shared, adding that they gradually scaled up from single-shift days to continuous operation.
Looking forward, Red Mesa plans to enter the Japanese market in 2025 and establish regional distribution hubs to serve global customers.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="993" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170227/Crystal-Resistant-CBD-Distillate-Anti-Crystallization-CBD-Red-Mesa-Science-and-Refining-1024x993.jpg" alt="" class="wp-image-636429" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170227/Crystal-Resistant-CBD-Distillate-Anti-Crystallization-CBD-Red-Mesa-Science-and-Refining-1024x993.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170227/Crystal-Resistant-CBD-Distillate-Anti-Crystallization-CBD-Red-Mesa-Science-and-Refining-300x291.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170227/Crystal-Resistant-CBD-Distillate-Anti-Crystallization-CBD-Red-Mesa-Science-and-Refining-768x745.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07170227/Crystal-Resistant-CBD-Distillate-Anti-Crystallization-CBD-Red-Mesa-Science-and-Refining.jpg 1114w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Crystal Resistant CBD Distillate Anti-Crystallization CBD Red Mesa Science and Refining</figcaption></figure>
While growth is a priority, so too is legislative reform. 
"The lack of clear rules for cannabinoid production is probably the biggest barrier we've seen to adoption. To bring prices down and make cannabinoids more accessible, we need efficient production coupled with thoughtful regulation," Applegate said. 
He emphasized that regulation and cost efficiency will help expand the market by making cannabinoids accessible to a wider consumer base.
Read Next:<a href="https://www.benzinga.com/general/biotech/24/08/40298228/think-you-can-do-it-all-20-000-reasons-why-automation-outperforms-a-broad-approach-in-cannabis"> Think You Can Do It All? 20,000 Reasons Why Automation Outperforms A Broad Approach In Cannabis</a>

Cannabis

Market Summary

News

Emerging Markets

Commodities

Economics

Success Stories

Exclusives

Markets

Tech

Interview

No Middleman, No Markup: How Red Mesa Is Slashing Costs With Around-The-Clock Hemp Refinement

Ethereum Classic (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/etc/usd">ETC</a>) has gained roughly 12% to $20.26 since Tuesday evening amid Donald Trump winning the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 presidential election</a>.
Trump&#8217;s win, coupled with the Republican Party regaining Senate control, hints at a shift in U.S. economic policies, potentially involving corporate tax cuts, trade tariffs and measures to combat inflation—factors that could influence both traditional and digital markets.
What To Know: A key driver behind Ethereum Classic's rally is Trump's pro-crypto stance, including his vision of the U.S. becoming a <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40671868/trumps-bitcoin-strategic-reserve-proposal-will-chip-away-dollars-status-warns-expert-money">&#8220;Bitcoin superpower.&#8221;</a> This renewed focus on cryptocurrencies as a store of value and inflation hedge has sparked investor interest in digital assets like Ethereum Classic, seen as a secure alternative to newer, more volatile coins.
Trump's anticipated economic policies could increase inflation, with experts predicting up to a 2.4% rise, pushing investors toward cryptocurrencies as a way to safeguard against the dollar&#8217;s decline. 
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/11/41826586/wall-street-closes-at-record-highs-after-reassurance-from-powell-magnificent-7-hit-17-trillion-tre">Wall Street Hits Record Highs After Powell&#8217;s Speech, Lifts Magnificent 7 Stocks To $17 Trillion In Historic Trading</a>
Ethereum Classic has also cultivated a strong following due to its decentralized nature and its adherence to the original Ethereum vision. As retail investors seek safe havens from economic uncertainty, the coin's appeal could grow in an environment marked by rising inflation fears.
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. <a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s Future of Digital Assets</a> event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.

$ETC

What's Going On With Ethereum Classic?

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

LIPO

In the wake of Donald Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 presidential win</a>, Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has jumped 10% since Wednesday to reach $0.00001944.
Trump's victory, combined with the Republican Party's return to a Senate majority, signals a potential shift in U.S. economic policy that includes corporate tax cuts, high tariffs and an aggressive stance on inflation—factors that could reshape traditional and digital asset markets alike.
What To Know: A key driver of SHIB&#8217;s surge is Trump's pro-crypto stance, marked by his vision of the U.S. as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40671868/trumps-bitcoin-strategic-reserve-proposal-will-chip-away-dollars-status-warns-expert-money">"Bitcoin superpower."</a> Trump's proposal to incorporate Bitcoin into a national reserve has sent ripples through the crypto space, igniting excitement among investors who see digital assets as hedges against economic uncertainty. 
Trump's anticipated policies could stoke inflationary pressures, with JPMorgan analysts projecting up to a <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2.4% rise in inflation</a> if trade tariffs are fully enacted. In such an environment, investors often look to alternative assets like cryptocurrencies as protection against the dollar's decline. 
Shiba Inu, with its low entry price and high volatility, is a popular speculative asset among retail investors seeking both growth potential and a potential hedge against macroeconomic risks.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41825733/could-micas-passport-system-open-doors-across-europe-for-crypto-exchanges">Could MiCA&#8217;s Passport System Open Doors Across Europe For Crypto Exchanges?</a>
Shiba Inu was created as an Ethereum-based alternative to Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), branding itself as the "Dogecoin killer." Both coins share a meme-inspired appeal, drawing in retail investors with their playful branding and community-driven support.
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. <a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a> event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.

$DOGE

$SHIB

What's Going On With Shiba Inu (SHIB)?

Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.10 by 120 percent. The company reported quarterly sales of $64.877 million which beat the analyst consensus estimate of $57.180 million by 13.46 percent. This is a 19.46 percent decrease over sales of $80.553 million the same period last year.

Earnings

Earnings Beats

CMTG

Claros Mortgage Trust Q3 2024 Adj. EPS $0.22 Beats $0.10 Estimate, Sales $64.877M Beat $57.180M Estimate

Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.90) by 106.67 percent. The company reported quarterly sales of $1.667 million which beat the analyst consensus estimate of $611.000 thousand by 172.83 percent. This is a 250.95 percent increase over sales of $475.000 thousand the same period last year.

CBUS

Cibus Q3 2024 Adj. EPS $0.06 , Sales $1.667M Beat $611.000K Estimate

President-elect Donald Trump has appointed his campaign leader, Susie Wiles, as his chief of staff. This marks the first time in US history that a woman has been appointed to this influential position.
What Happened: Wiles, a seasoned GOP operative from Florida, will assume her new role when Trump takes office in January. Trump lauded Wiles for her pivotal role in his successful 2016 and 2020 campaigns, <a href="https://thehill.com/homenews/4979786-susie-wiles-chief-of-staff/">reported</a> The Hill.
&#8220;Susie is tough, smart, innovative, and is universally admired and respected. Susie will continue to work tirelessly to Make America Great Again,&#8221; said Trump, reported The Hill.
He said, &#8220;It is a well deserved honor to have Susie as the first-ever female Chief of Staff in United States history. I have no doubt that she will make our country proud.&#8221;
Wiles, known for her low-profile approach, spearheaded Trump&#8217;s Florida operations during the 2016 campaign and later collaborated with Ron DeSantis (R) on his gubernatorial campaign. However, she left DeSantis&#8217;s team due to escalating tensions.
The chief of staff role, second only to the president in terms of influence, will see Wiles managing Trump and his team, a task that proved challenging during his first term. Trump&#8217;s initial choice for the role, Reince Priebus, was replaced after six months by John Kelly, who later became a vocal critic of Trump.
See Also: <a href="https://www.benzinga.com/news/24/11/41710411/market-analyst-who-predicted-trumps-2016-win-and-bidens-2020-victory-now-sees-former-president-retak?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Market Analyst Who Predicted Trump&#8217;s 2016 Win And Biden&#8217;s 2020 Victory, Now Sees Former President Retaking The White House With &#8216;Large Majority Of Swing States&#8217;</a>
Why It Matters: Wiles&#8217; appointment comes on the <a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f">heels of Trump&#8217;s victory</a> in the 2024 presidential election. Trump&#8217;s win, which he described as &#8220;the greatest political movement of all time,&#8221; was followed by a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41807254/trump-election-raises-odds-of-roaring-2020s-scenario-veteran-wall-street-investor-s">surge in the U.S. stock market</a>, with analysts predicting a new &#8220;Roaring 2020s&#8221; scenario.
On Wednesday, after Trump won the election, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) shot up 2.5% to establish new record highs. The small-caps fund iShares Russell 2000 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) spiked 5.8%.
However, Trump also hinted at a <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">potential senior role</a> for Robert Kennedy Jr. to advance his &#8220;Make America Healthy Again&#8221; agenda, causing uncertainty in pharmaceutical stocks.
With Wiles at the helm as chief of staff, it remains to be seen how these developments will unfold and shape the course of Trump&#8217;s second term in office.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Trump Appoints Susie Wiles As First Woman Chief Of Staff In US History, Calls Her Tough, Smart And Innovative

Galiano Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#AMEX">GAU</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 40 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $71.130 million which missed the analyst consensus estimate of $78.000 million by 8.81 percent. This is a 5.22 percent increase over sales of $67.600 million the same period last year.

Earnings Misses

Galiano Gold Q3 2024 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $71.130M Miss $78.000M Estimate

HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. The company reported quarterly sales of $9.416 million which beat the analyst consensus estimate of $8.950 million by 5.21 percent. This is a 1.56 percent increase over sales of $9.271 million the same period last year.

HireQuest Q3 2024 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $9.416M Beat $8.950M Estimate

Donald Trump will return to the White House and will bring major changes to the country's tax, AI and energy policies. RBC Capital Markets analyst Deane Dray highlighted some of the companies that may benefit <a href="https://www.benzinga.com/government/24/11/41828468/trump-says-hed-replace-income-taxes-with-tariffs-the-potential-economic-fallout">from Trump's policies. </a>
Fossil Fuel/ Energy Independence: Trump's plans for energy independence would reverse many of the Biden administration's policies in order to reinvigorate the fossil fuel industry. He aims to expand the construction of pipelines, grids, ports and refineries and emphasizes utilizing domestic oil, gas and coal resources. Dray pointed to Flowserve Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) and Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) as potential beneficiaries of Trump's energy policies. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Rollback of IRA/ Reduced Clean Energy Investments: Trump has said he plans<a href="https://www.benzinga.com/news/24/07/39854007/trump-says-he-will-end-the-electric-vehicle-mandate-on-day-one-days-after-tesla-ceo-elon-musks-endor"> to eliminate</a> many vehicle emissions standards under the Environmental Protection Agency as well as many EV incentives included in the Biden administration&#8217;s Inflation Reduction Act (IRA). 
The RBC analyst again pointed to oil and gas companies as the key companies that could benefit from these potential policy adjustments, but cautioned it is too early to tell what the impacts might be for nuclear power companies. 
More Flexible/Reduced AI Regulation: RBC expects a Trump administration to be in favor of Big Tech and AI developers as he has called for a review of "unnecessary and burdensome regulations" on AI. The firm also pointed out that multi-industry data center-exposed stocks outperformed the sector by 500 basis points the day after Trump won the election. 
Dray said multi-industry companies involved in data centers that could benefit from Trump's less restrictive AI policies include nVent Electric Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) and Eaton Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>). 
Lower Corporate Tax Rate: Trump <a href="https://www.benzinga.com/government/24/10/41623850/trump-vs-harris-how-the-candidates-corporate-tax-proposals-stack-up">shared his plans</a> to lower the corporate tax rate to 15% for companies that make their products in the U.S. The RBC analyst sees lower corporate tax rates could lead to more reshoring from semiconductor and pharmaceutical companies and potentially more investment in the US. 
Dray pointed to Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) specifically, but most publicly traded companies could benefit from lower tax rates. 
The Takeaway: "The bottom line is that early stock moves are playing out according to script, with the early stock outperformers being the electricals and oil and gas exposed names," Dray wrote. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Shutterstock

Government

Movers

How To Play The 'Trump Trade' For AI, Energy, Taxes: Analyst Says 5 Stocks Could Shine

Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(2.03) by 10.34 percent. The company reported quarterly sales of $1.650 million which beat the analyst consensus estimate of $1.635 million by 0.92 percent. This is a 9.19 percent decrease over sales of $1.817 million the same period last year.

AVGR

Avinger Q3 2024 GAAP EPS $(1.82) Beats $(2.03) Estimate, Sales $1.650M Beat $1.635M Estimate

Globalstar (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#AMEX">GSAT</a>) raises FY2024 sales outlook from $235.00 million-$250.00 million to $245.00 million-$250.00 million.

Guidance

GSAT

Globalstar Raises FY2024 Sales Guidance from $235.00M-$250.00M to $245.00M-$250.00M

VistaGen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 36.36 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $183.000 thousand which missed the analyst consensus estimate of $223.333 thousand by 18.06 percent. This is a 34.10 percent decrease over sales of $277.700 thousand the same period last year.

VTGN

VistaGen Therapeutics Q2 2025 GAAP EPS $(0.42) Misses $(0.39) Estimate, Sales $183.000K Miss $223.333K Estimate

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) reported quarterly losses of $(1.72) per share. This is a 37.6 percent decrease over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $78.795 million which beat the analyst consensus estimate of $73.225 million by 7.61 percent. This is a 25.62 percent increase over sales of $62.723 million the same period last year.

NUTX

Nutex Health Q3 2024 GAAP EPS $(1.72) Down From $(1.25) YoY, Sales $78.795M Beat $73.225M Estimate

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.78 by 17.95 percent. The company reported quarterly sales of $23.366 billion which beat the analyst consensus estimate of $22.574 billion by 3.51 percent. This is a 8.56 percent decrease over sales of $25.552 billion the same period last year.

PBR/A

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares Q3 2024 GAAP EPS $0.92 Beats $0.78 Estimate, Sales $23.366B Beat $22.574B Estimate

MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 200 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.079 million which missed the analyst consensus estimate of $74.500 million by 5.93 percent. This is a 36.73 percent increase over sales of $51.253 million the same period last year.

MNKD

MannKind Q3 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $70.079M Miss $74.500M Estimate

Goldman Sachs BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSBD#NYSE">GSBD</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.55 by 3.64 percent. The company reported quarterly sales of $110.413 million which missed the analyst consensus estimate of $115.264 million by 4.21 percent. This is a 8.03 percent decrease over sales of $120.056 million the same period last year.

GSBD

Goldman Sachs BDC Q3 2024 Adj. EPS $0.57 Beats $0.55 Estimate, Sales $110.413M Miss $115.264M Estimate

BanColombia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIB#NYSE">CIB</a>) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.43 by 4.2 percent. The company reported quarterly sales of $1.257 billion which missed the analyst consensus estimate of $1.573 billion by 20.10 percent. This is a 4.92 percent increase over sales of $1.198 billion the same period last year.

BanColombia Q3 2024 GAAP EPS $1.49 Beats $1.43 Estimate, Sales $1.257B Miss $1.573B Estimate

The 2028 presidential election will be held on Nov. 7, 2028, and is over 1,400 days away but that hasn't stopped sportsbooks and prediction markets from forecasting who will win the next election after Donald Trump claimed victory in the<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> 2024 presidential election.</a>
2028 Election Betting Odds: While betting on U.S. elections is illegal for American sportsbooks, there are betting odds at sportsbooks around the world. Prediction markets and online stock brokerages have also<a href="https://www.benzinga.com/fintech/24/11/41783293/robinhood-reports-record-overnight-trading-volume-400-million-2024-election-contracts-traded"> launched regulated election contract options</a> in recent months.
Here is an early look at the 2028 election betting odds.
From Bookies.com, here are the current betting <a href="https://bookies.com/news/2028-us-presidential-election-odds-who-will-succeed-donald-trump">odds</a>:
<ul>
<li>J.D. Vance (Republican): +450</li>
<li>Gavin Newsom (Democrat): +575</li>
<li>Ron DeSantis (Republican): +700</li>
<li>Michelle Obama (Democrat): +950</li>
<li>Josh Shapiro (Democrat): +1,000</li>
<li>Kamala Harris (Democrat): +1,200</li>
<li>Andy Beshear (Democrat): +1,200</li>
<li>Nikki Haley (Republican): +1,200</li>
<li>Vivek Ramaswamy (Republican): +1,300</li>
<li>Wes Moore (Democrat): +1,700</li>
<li>Tom Cotton (Democrat): +1,700</li>
<li>Glenn Youngkin (Republican): +2,500</li>
<li>Aaron Rodgers (Independent): +3,000</li>
<li>Dwayne Johnson (Democrat): +3,500</li>
<li>Mark Cuban (Democrat): +3,500</li>
<li>Field (All others including Gretchen Whitmer, Marco Rubio, Ted Cruz): +2,000</li>
</ul>
Here are the current betting odds from SportsBettingDimes:
<ul>
<li>J.D. Vance (Republican): +300</li>
<li>Michelle Obama (Democrat): +500</li>
<li>Gavin Newsom (Democrat): +550</li>
<li>Ron DeSantis (Republican): +800</li>
<li>Tulsi Gabbard (Republican): +1,000</li>
<li>Hillary Clinton (Democrat): +1,400</li>
<li>Tucker Carlson (Republican): +1,400</li>
<li>Nikki Haley (Republican): +2,500</li>
<li>Oprah Winfrey (Democrat): +2,500</li>
<li>Kamala Harris (Democrat): +2,500</li>
</ul>
Bet365 does not currently list individual betting odds for who will win but has the option to bet on which party will win with Republicans favored at -150 implying a 60% chance of winning with Democrats the underdog at +120, as reported by <a href="https://www.covers.com/politics/2028-us-election-odds-republican-party-favored-nov-6-2024">Covers</a>.
Prediction market Kalshi, which is legal to U.S. bettors, also has several betting markets open for 2028 including the winning <a href="https://kalshi.com/markets/kxpresparty/party-winning-presidency">party </a>with Republicans at 49% and Democrats at 51%.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomr/republican-primary-winner">odds </a>on Kalshi for the Republican Party nominee for the 2028 election:
<ul>
<li>J.D. Vance: 57%</li>
<li>Donald Trump Jr.: 7%</li>
<li>Ron DeSantis: 6%</li>
<li>Donald Trump: 4%</li>
<li>Glenn Youngkin: 4%</li>
<li>Vivek Ramaswamy: 4%</li>
</ul>
The 22nd Amendment currently would keep Trump from serving more than two terms in the White House, but he's included in Kalshi's odds here.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomd/democratic-primary-winner#kxpresnomd-28">odds </a>on Kalshi for the Democrat Party nominee for the 2028 election:
<ul>
<li>Gavin Newsom: 16%</li>
<li>Josh Shapiro: 16%</li>
<li>Gretchen Whitmer: 14%</li>
<li>Pete Buttigieg: 11%</li>
<li>Wes Moore; 9%</li>
<li>J.B. Pritzker: 9%</li>
<li>Alexandria Ocasio-Cortez: 7%</li>
<li>Michelle Obama: 6%</li>
<li>Kamala Harris: 2%</li>
</ul>
Polymarket, which <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41694948/trump-polymarket-whale-has-30m-bet-on-former-president-winning-2024-election-my-intent-is-">had many prediction markets</a> on the 2024 election does not currently offer 2028 markets. The decentralized platform allows users to deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). The platform will be closely watched in the coming months to see who takes the early lead in 2028 election betting.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Polymarket saw over $3 billion bet on the 2024 election winner market with various other markets attracting high betting volume.
Kalshi had over $100 million wagered on<a href="https://www.benzinga.com/general/politics/24/11/41701133/more-than-100m-wagered-on-presidential-race-on-kalshi"> the 2024 election outcome.</a>
Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) had over 400 million contracts traded during the 2024 election.
While betting on the outcomes of U.S. elections is not legal at sportsbooks for America, people around the world were placing wagers along with prediction markets and brokerages trading contracts to take advantage of strong user demand.
By the time the 2028 election rolls around there could be even more betting options and election betting<a href="https://www.benzinga.com/general/sports-betting/23/05/32244769/exclusive-draftkings-benefits-from-non-nfl-sports-growth-eyes-horse-racing-and-election-be"> could be legal at sportsbooks. </a>While things could look different in the coming years, the betting odds above will likely look different as candidates decide to run or withdraw their names from consideration.
It's likely not a surprise that Vance is the early betting favorite as the future vice president won the 2024 election ticket with Trump and would be the frontrunner for the Republican Party. The big question is if Harris will run for president again and if not her, who will be the frontrunner for the Democratic Party.
Harris <a href="https://www.benzinga.com/general/sports-betting/24/10/41347270/trump-vs-harris-2024-election-polls-sportsbooks-betting-odds-show-different-winners-for-20">was the favorite </a>at +350 for the 2024 election after Joe Biden won the 2020 election as the current president originally said he would not run a second term. Biden and Trump trailed Harris in January 2021 betting odds to win the 2024 race at +400 and +650, respectively.
With Biden running again, the odds favored Biden, Trump and DeSantis, who ran in the Republican primary, for many months. With Biden dropping out, sportsbooks favored Harris before the odds shifted to Trump in the months leading up to the 2024 election.
While an Independent candidate has never won the election, the listing of Rodgers, who is the quarterback of the NFL's New York Jets, has captured some attention.
"I can't believe we live in a world where my QB has better odds to win the 2028 presidential election than my team does to win the Super Bowl," X user @blakenyjets <a href="https://x.com/blakenyjets/status/1854291783754363114">said</a>.
The New York Jets, who started the season as one of the favorites to win Super Bowl LIX, are currently 3-6 and the odds at DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) of a Super Bowl victory are +2,500 today.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41819799/polymarket-ceo-on-election-night-it-looked-like-a-done-deal-on-platform-but-just-watching-">Polymarket CEO On Election Night: &#8216;It Looked Like A Done Deal&#8217; On Platform, But Just Watching TV &#8216;You Would Think It&#8217;s Neck And Neck&#8217;</a></li>
</ul>
Photo: Meeboonstudio via Shutterstock

Sports Betting

$ETH

$MATIC

$USDC

DKNG

HOOD

USDC

2028 Election Betting Odds: Where Do J.D. Vance, Michelle Obama, Mark Cuban, Ron DeSantis, Kamala Harris Rank?

Fulgent Genetics Q2 2024 Earnings Preview

Fulgent Genetics beats top-line and bottom-line estimates; updates FY24 EPS outlook

An update from Fulgent Genetics (FLGT) is now available. Fulgent Genetics has updated its investor presentation on August 2, 2024, offering fresh i...

Fulgent Genetics Releases Updated Investor Presentation

Fulgent Genetics, Inc. (FLGT) Q2 2024 Earnings Call Transcript

Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst

OraSure Technologies: Nursing A COVID-19 Hangover

Fulgent Genetics: An NCAV Pick With Profit And Growth Potential

Fulgent Genetics (FLGT) announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs, or VA, to provide hereditary...

Fulgent Genetics awarded $99M contract by VA

Fulgent Genetics Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

ADNT

AMCX

AMRX

ANIP

ATSG

BEPC

BLMN

CBWTF

CRLBF

DCBO

FLGT

HUMA

ICAGY

IFRX

ILLMF

LAMR

OCGN

OSUR

PAGP

PARAA

QTRHF

RCMT

SONY

XERS

Press Releases

Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024

Fulgent Reports Second Quarter 2024 Financial Results

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

Fulgent to Participate in Upcoming Conferences

Accolade

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Biodesix

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Fulgent Genetics

Interés en corto

Fulgent Genetics (NASDAQ:FLGT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL